A novel, potentially disease-modifying treatment for Alzheimer’s disease is set to begin a Phase 2a clinical trial, designed to evaluate efficacy over a time frame of 6 months, across 7 study sites in Australia. ANAVEX 2-73, a pipeline product of Anavex Life Sciences Corp.,…
The National Institutes of Health (NIH) has granted $5.5 million in funding to expand the first large-scale study that aims to identify drugs able to stop or slow the progression of Alzheimer’s disease, which is being conducted by the Washington University School of Medicine in St. Louis. The National…
Dr. Rachelle Doody One of the authorities in Alzheimer’s disease, Dr. Rachelle Doody, is scheduled to give a lecture on the latest updates and developments on the disease, a form of dementia that is estimated to affect at least 5.2 million Americans in 2014…
In a special issue of the Cell Press journal Neuron, experts debated the challenges associated with “translational neuroscience,” and the efforts that should be made to commercialize advances made in the laboratory so that patients can benefit from them. Despite the major advances that science is making in understanding…
Self-reported sleep disturbances may be related to a higher risk of developing Alzheimer’s disease, according to the results of a study conducted at Uppsala University, in Sweden, which were recently published at the Alzheimer’s & Dementia journal. The researchers analyzed data that included 40 years of self-reports, and…
A new study published in the journal Neuropharmacology revealed that drugs used to treat type 2 diabetes can actually help to reverse Alzheimer’s disease. According to Professor Christian Holscher of Lancaster University and the lead scientist of the study, drugs for type 2 diabetes were continuously tested in…
A study published in the British Journal of Psychiatry argues that people who are shorter have a higher risk of developing dementia — an increased risk that is particularly found in men. According to the study’s author, being short does not cause dementia, but how tall a person is could…
Anavex Life Sciences Corp. will initiate a Phase 2a clinical trial for the treatment of Alzheimer’s disease with their compounds – ANAVEX 2-73 and ANAVEX PLUS – after receiving regulatory approval by the Ethics Committee in Australia. ANAVEX 2-73, an orally available drug candidate, is under investigation to treat…
In a study published in the online issue of Molecular Neurodegeneration journal, a team of researchers at Georgetown University Medical Center (GUMC), in collaboration with researchers at the Capital Medical University in Beijing, China and funded by Merck Research Laboratories, shows that Tau protein is the key triggering event to…
A multi-institutional team of British researchers has determined that evidence suggests a high prevalence of comorbid medical conditions and related complaints among people with dementia, and that the presence of dementia may complicate clinical care for other conditions, and undermine a patient’s ability to manage a chronic condition. The…
Get regular updates to your inbox.